Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease

V2, Crosslink

🧫

Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-lipid-dr

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease ## Background and Rationale This clinical trial investigates a novel therapeutic approach targeting the lipid droplet-lysosome axis in Parkinson's disease (PD), addressing critical gaps in current treatment paradigms. PD pathogenesis involves complex interactions between protein aggregation, lipid metabolism dysfunction, and impaired autophagy-lysosomal clearance mechanisms. Recent evidence suggests that lipid droplets (LDs

METHODOLOGY NOTES

Phase 1 (Weeks 1-4): Screening and baseline assessments including comprehensive medical history, UPDRS evaluation, Montreal Cognitive Assessment (MoCA), DaTscan imaging, lumbar puncture for CSF collection, and blood sampling for lipid profiling and inflammatory markers. Participants undergo pharmacogenomic testing and medication washout period. Phase 2 (Weeks 5-8): Randomization to treatment (n=75) or placebo (n=75) groups. Treatment arm receives combination therapy: compound targeting acetyl-CoA carboxylase (200mg twice daily) plus lysosomal enhancer promoting TFEB nuclear translocation (150mg daily) plus standard levodopa therapy. Placebo group receives matching inert capsules plus levodopa. Weekly safety assessments monitor liver function, lipid panels, and adverse events. Phase 3 (Weeks 9-24): Continuation phase with monthly clinical evaluations including UPDRS Parts I-IV, Parkinson's Disease Questionnaire-39, and Epworth Sleepiness Scale. Biomarker sampling at weeks 12 and 24 incl

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.899741Z'}
summary	# Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease ## Background and Rationale This clinical trial investigates a novel therapeutic approach targeting the lipid droplet-lysosome
entities	{'genes': ['CERS2/DGAT1/LAMP1'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease
methodology_notes	Phase 1 (Weeks 1-4): Screening and baseline assessments including comprehensive medical history, UPDRS evaluation, Montreal Cognitive Assessment (MoCA), DaTscan imaging, lumbar puncture for CSF collec
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.899747', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

693

Outgoing

644

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease

derives from (16)

supports (55)

💬 Discussion